Medivir files for EU approval of Lipsovir

Sweden's Medivir has now submitted an application for marketing authorization to the European regulatory authorities for Lipsovir, a topical product for prevention and treatment of cold sores.

Lipsovir is a patented combination of the anti-inflammatory agent hydrocortisone and the antiviral acyclovir in a proprietary cream base developed by Medivir.

The clinical Phase III program demonstrated that the development of cold sores can be prevented with early treatment initiation, an effect that currently-available products for this indication lack. Lipsovir thereby provides individuals prone to recurrent cold sores with a clinically-important benefit compared to agents now marketed, according to the Swedish firm.